+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease



Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease



Cancer 88(9): 2142-2148



BACKGROUND. Combination chemotherapy, including hybrid regimens, is the standard treatment for patients with advanced Hodgkin disease (HD). Although a prolonged complete response (CR) is achieved in up to 70-80% of patients, long term complications, such as secondary leukemia, are of concern. Cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) is a hybrid chemotherapy in which cyclophosphamide is substituted for mechlorethamine, an agent that has been implicated as the cause of secondary malignancies. METHODS. Seventy-three patients (37 males and 36 females; median age, 35 years) diagnosed with Stage III or IV HD or Stage II with bulky disease, B-symptoms, elevated erythrocyte sedimentation rate, or hilar adenopathy were treated with 8 courses of C-MOPP/ABV at a single institution during a 6-year period. Radiotherapy (RT) was administered when bulky disease or residual masses were present. Endpoints of the study were response to therapy, failure free survival (FFS), overall survival (OS), and toxicity. RESULTS. Sixty-five patients (90%) received the 8 planned courses, with 49 of them (70%) receiving the full prescribed doses. After chemotherapy, 57 patients (78%) reached CR. Seven additional patients who achieved partial response (PR) reached CR after complementary radiotherapy, with an overall CR rate of 88%. The median follow-up was 31 months. Twelve patients relapsed; the 4-year FFS was 66% (95% CI, 54-78%). Two patients died during treatment because of sepsis and four due to disease progression. The 4-year OS was 92% (95% CI, 86-98%). Age > 60 years and bone marrow involvement were related to severe infectious complications. No late toxicity was reported. CONCLUSIONS. C-MOPP/ABV induces CR with acceptable toxicity in a high proportion of advanced HD patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010769573

Download citation: RISBibTeXText

PMID: 10813727

DOI: 10.1002/(sici)1097-0142(20000501)88:9<2142::aid-cncr21>3.0.co;2-m


Related references

Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Cancer Treatment Reports 68(7-8): 947-951, 1984

Alternating Combination Chemotherapy C-Mopp (Cyclophosphamide, Vincristine, Procarbazine, Prednisone) and Abvd (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) in Clinical Stage Ii-Iv Hodgkin's Disease: a Multicenter Phase Ii Study (Jcog 8905). Japanese Journal of Clinical Oncology 30(3): 146-152, 2000

Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP. Cancer 38(1): 42-48, 1976

Chemotherapy of hodgkin's lymphoma with alternating cycles of copp cyclophosphamide vincristine procarbazine prednisone and abvd doxorubicin bleomycin vinblastine and dacarbazine results of the hd1 and hd3 trials of the german hodgkin study group. Medical Oncology and Tumor Pharmacotherapy 6(2): 155-162, 1989

Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone. Cancer Treatment Reports 67(5): 413-419, 1983

Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy. Medical and Pediatric Oncology 29(1): 23-27, 1997

Results of the treatment of hodgkin's disease in stages iii and iv with use of the doxorubicin bleomycin vinblastine dacarbazine and bleomycin doxorubicin cyclophosphamide vincristine prednisone programs. Acta Haematologica Polonica 17(3-4): 81-90, 1986

Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 22(12): 2424-2429, 2004

Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Japanese Journal of Clinical Oncology 30(3): 146-152, 2000

Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone). Polskie Archiwum Medycyny Wewnetrznej 86(4): 274-280, 1991

Treatment outcome of advanced Hodgkin's disease based on using an alternating program ChLVPP (chlorambucil, vinblastine, procarbazine, prednisone) and ABV (doxorubicin, bleomycin, vinblastine). Acta Haematologica Polonica 25(4): 363-368, 1994

Chlorambucil vinblastine procarbazine and prednisone ch1vpp an effective but less toxic regimen than mopp mechlorethamine vincristine prednisone procarbazine for advanced stage hodgkin's disease. Proceedings of the American Association for Cancer Research Annual Meeting 27: 198, 1986

Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Cancer Treatment Reports 71(12): 1203-1207, 1987

Gonadal toxicity after combination chemotherapy for hodgkins disease comparative results of mopp mechlorethamine vincristine procarbazine and prednisone vs. adriamycin bleomycin vinblastine and dacarbazine. European Journal of Cancer and Clinical Oncology 21(5): 601-606, 1985

Chemotherapy vs radiotherapy for remission consolidation after three double cycles of cyclophosphamide vincristine procarbazine prednisone copp and doxorubicin bleomycin vinblastine dacarbazine abvd a randomized trial in patients with stages iiib iv hodgkins lymphoma. Journal of Cancer Research & Clinical Oncology 116(Suppl. Part 1): 613, 1990